Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
Phase 4
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]Drug: ribavirin [Copegus]
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT01585324
A Non-Drug Study of The Suitability of Neurocognitive Tests And Functioning Scales For The Measurement of Cognitive And Functioning Changes in Individuals With Down Syndrome
Completed
- Conditions
- Down Syndrome
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT01580384
A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment
Phase 2
Withdrawn
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: RO5024048Drug: danoprevirDrug: peginterferon alfa-2a [Pegasys]Drug: ribavirin [Copegus]Drug: ritonavir
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01579019
Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 184
- Registration Number
- NCT01579006
An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis
Phase 3
Terminated
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Drug: RoActemra/Actemra (tocilizumab)
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT01575769
- Locations
- 🇵🇱
Wojewodzki Szpital Dzieciecy Im. J. Brudzinskiego, Bydgoszcz, Poland
🇷🇺SI Sceintific children health center RAMS, Moscow, Russian Federation
🇷🇺GOU VPO Rostovskiy state medical university Roszdrav, Rostov-na-donu, Russian Federation
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
Phase 3
Completed
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1436
- Registration Number
- NCT01572038
- Locations
- 🇦🇷
Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina
🇦🇹LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria
🇧🇪UZ Brussel, Brussel, Belgium
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2577
- Registration Number
- NCT01566721
- Locations
- 🇩🇴
Hospital Metropolitano de Santiago, Santiago, Dominican Republic
🇫🇷Clinique Tivoli; Sce Radiotherapie, Bordeaux, France
🇪🇨Solca Guayaquil- Sociedad de Lucha Contra El Cáncer; Oncology, Guayaquil, Ecuador
A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 213
- Registration Number
- NCT01565083
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT01564901
An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01565122
© Copyright 2025. All Rights Reserved by MedPath